<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01987349</url>
  </required_header>
  <id_info>
    <org_study_id>SU-17219-2009</org_study_id>
    <secondary_id>2U19AI057229-06</secondary_id>
    <nct_id>NCT01987349</nct_id>
  </id_info>
  <brief_title>T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) - Year 1, 2009</brief_title>
  <official_title>Protective Mechanisms Against a Pandemic Respiratory Virus: B- Cell, T-cell, and General Immune Response to Seasonal Influenza Vaccine. Year 1, 2009</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will compare influenza vaccine responses in monozygotic and dizygotic twins.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators plan to study the response to different influenza vaccines much more
      broadly and deeply across different age groups and with different vaccine modalities and to
      probe the influence of genetics on these responses using monozygotic and dizygotic twins.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants From Each Arm Who Received Influenza Vaccine Vaccine</measure>
    <time_frame>Day 0 to 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Related Adverse Events</measure>
    <time_frame>Day 0 to 28 post-immunization</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Lymphocyte Response to Influenza Immunization</measure>
    <time_frame>Day 6-28 post-immunization</time_frame>
    <description>Compare lymphocyte responses at Days 6-14 and the lymphocyte and serology responses at Day 28 post-immunization following annual administration of the influenza vaccines</description>
  </other_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Group A: age 8-17 yo identical twins</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants will be randomized to receive either Fluzone® (intramuscular) or FluMist® (intranasal)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B: 18-30 yo identical twins</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants to receive FluMist® (intranasal)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C: 18-30 yo fraternal twins</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants to receive FluMist® (intranasal)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D: 40-49 yo identical twins</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants to receive FluMist® (intranasal)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group E: 40-49 yo fraternal twins</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants to receive FluMist® (intranasal)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group F: 70-100 yo twins</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants to receive Fluzone® (intramuscular)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group G: 70-100 yo non-twins</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants to receive Fluzone® (intramuscular)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fluzone® (intramuscular)</intervention_name>
    <description>Licensed seasonal trivalent inactivated influenza vaccine (IIV3)</description>
    <arm_group_label>Group A: age 8-17 yo identical twins</arm_group_label>
    <arm_group_label>Group F: 70-100 yo twins</arm_group_label>
    <arm_group_label>Group G: 70-100 yo non-twins</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>FluMist® (intranasal)</intervention_name>
    <description>Licensed trivalent seasonal live attenuated influenza vaccine (LAIV3)</description>
    <arm_group_label>Group A: age 8-17 yo identical twins</arm_group_label>
    <arm_group_label>Group B: 18-30 yo identical twins</arm_group_label>
    <arm_group_label>Group C: 18-30 yo fraternal twins</arm_group_label>
    <arm_group_label>Group D: 40-49 yo identical twins</arm_group_label>
    <arm_group_label>Group E: 40-49 yo fraternal twins</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Otherwise healthy, ambulatory children or adults, ages 8-17 years (identical twin
             pairs), 18-30 years (identical or fraternal twin pairs), 40-49 years (identical or
             fraternal twin pairs) or 70-100 years (twin or non-twin adults).

          2. Willing to complete the informed consent process.

          3. Availability for follow-up for the planned duration of the study at least 28 days
             after immunization.

          4. Acceptable medical history and vital signs.

          5. Negative urine pregnancy test for women of childbearing potential

          6. If the subject is female and of childbearing potential, she must use an acceptable
             method of contraception and not become pregnant for the duration of the study.
             (Acceptable contraception includes implants, injectables, combined oral
             contraceptives, effective intrauterine devices (IUDs), sexual abstinence, or a
             vasectomized partner).

        Exclusion Criteria:

          1. Prior vaccination with TIV or LAIV in Fall 2009

          2. Allergy to egg or egg products, or to vaccine components, including gentamicin,
             gelatin, arginine or MSG (for LAIV only), or thimerosal (TIV multidose vials only).

          3. Life-threatening reactions to previous influenza vaccinations

          4. Asthma (LAIV groups only)

          5. Active systemic or serious concurrent illness, including febrile illness on the day of
             vaccination

          6. History of immune deficiency

          7. Known or suspected impairment of immunologic function, including, but not limited to,
             clinically significant liver disease, diabetes mellitus treated with insulin, moderate
             to severe renal disease, blood pressure &gt;150/95 at screening, or any other chronic
             disorder which, in the opinion of the investigator, might jeopardize volunteer safety
             or compliance with the protocol.

          8. Hospitalization in the past year for congestive heart failure or emphysema.

          9. Chronic Hepatitis B or C

         10. Recent or current use of immunosuppressive medication, including glucocorticoids
             (corticosteroid nasal sprays are permissible).

         11. Subjects in close contact with anyone who has a severely weakened immune system should
             not receive LAIV.

         12. Malignancy, other than squamous cell or basal cell skin cancer (includes solid tumors
             such as breast cancer or prostate cancer with recurrence in the past year, and any
             hematologic cancer such as leukemia).

         13. Autoimmune disease (including rheumatoid arthritis treated with immunosuppressive
             medication such as Plaquenil, methotrexate, prednisone, Enbrel) which, in the opinion
             of the investigator, might jeopardize volunteer safety or compliance with the
             protocol.

         14. History of blood dyscrasias, renal disease, or hemoglobinopathies requiring regular
             medical follow up or hospitalization during the preceding year

         15. Use of any anti-coagulation medication such as Coumadin or Lovenox, or anti-platelet
             agents such as aspirin, Plavix, Aggrenox may be acceptable after review by
             investigator.

         16. Receipt of blood or blood products within the past 6 months

         17. Medical or psychiatric condition or occupational responsibilities that preclude
             subject compliance with the protocol

         18. Inactivated vaccine 14 days prior to vaccination

         19. Live, attenuated vaccine within 60 days of vaccination

         20. History of Guillain-Barre Syndrome

         21. Pregnant or lactating woman

         22. Use of investigational agents within 30 days prior to enrollment

         23. Donation of the equivalent of a unit of blood within 6 weeks prior to enrollment

         24. Any condition which, in the opinion of the investigator, might interfere with
             volunteer safety, study objectives or the ability of the participant to understand or
             comply with the study protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cornelia L Dekker, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark M Davis, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Garry Nolan, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ann Arvin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stephen Quake, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://vaccines.stanford.edu/clinical_trials.html</url>
    <description>Stanford LPCH Vaccine Program Clinical Trials Website</description>
  </link>
  <reference>
    <citation>Horowitz A, Strauss-Albee DM, Leipold M, Kubo J, Nemat-Gorgani N, Dogan OC, Dekker CL, Mackey S, Maecker H, Swan GE, Davis MM, Norman PJ, Guethlein LA, Desai M, Parham P, Blish CA. Genetic and environmental determinants of human NK cell diversity revealed by mass cytometry. Sci Transl Med. 2013 Oct 23;5(208):208ra145. doi: 10.1126/scitranslmed.3006702.</citation>
    <PMID>24154599</PMID>
  </reference>
  <reference>
    <citation>Brodin P, Jojic V, Gao T, Bhattacharya S, Angel CJ, Furman D, Shen-Orr S, Dekker CL, Swan GE, Butte AJ, Maecker HT, Davis MM. Variation in the human immune system is largely driven by non-heritable influences. Cell. 2015 Jan 15;160(1-2):37-47. doi: 10.1016/j.cell.2014.12.020.</citation>
    <PMID>25594173</PMID>
  </reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 24, 2013</study_first_submitted>
  <study_first_submitted_qc>November 12, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2013</study_first_posted>
  <results_first_submitted>January 11, 2017</results_first_submitted>
  <results_first_submitted_qc>April 3, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 12, 2017</results_first_posted>
  <last_update_submitted>April 3, 2017</last_update_submitted>
  <last_update_submitted_qc>April 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Cornelia L. Dekker</investigator_full_name>
    <investigator_title>Professor, Pediatrics</investigator_title>
  </responsible_party>
  <keyword>Influenza vaccines</keyword>
  <keyword>healthy participants</keyword>
  <keyword>immunity to influenza</keyword>
  <keyword>identical twins</keyword>
  <keyword>fraternal twins</keyword>
  <keyword>non-twins</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Numbers listed in the tables reflect individual twins and not twin pairs.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Group A: Age 8-17 yo Identical Twins</title>
          <description>Participants will be randomized to receive Fluzone® (intramuscular)</description>
        </group>
        <group group_id="P2">
          <title>Group A: Age 8-17yo Identical Twins</title>
          <description>Participants will be randomized to receive FluMist® (intranasal)</description>
        </group>
        <group group_id="P3">
          <title>Group B: Age 18-30 yo Identical Twins</title>
          <description>Participants to receive FluMist® (intranasal)</description>
        </group>
        <group group_id="P4">
          <title>Group C: Age 18-30 yo Fraternal Twins</title>
          <description>Participants to receive FluMist® (intranasal)</description>
        </group>
        <group group_id="P5">
          <title>Group D: Age 40-49 yo Identical Twins</title>
          <description>Participants to receive FluMist® (intranasal)</description>
        </group>
        <group group_id="P6">
          <title>Group E: Age 40-49 yo Fraternal Twins</title>
          <description>Participants to receive FluMist® (intranasal)</description>
        </group>
        <group group_id="P7">
          <title>Group F: 70-100 yo Identical Twins</title>
          <description>Participants to receive Fluzone® (intramuscular)</description>
        </group>
        <group group_id="P8">
          <title>Group G: 70-100 yo Nontwins</title>
          <description>Participants to receive Fluzone® (intramuscular)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="10"/>
                <participants group_id="P8" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="10"/>
                <participants group_id="P8" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Participants between the ages of 8 - 100 years old.</population>
      <group_list>
        <group group_id="B1">
          <title>Group A: Age 8-17 yo Identical Twins (Fluzone)</title>
          <description>Participants will be randomized to receive Fluzone® (intramuscular)</description>
        </group>
        <group group_id="B2">
          <title>Group A: Age 8-17 yo Identical Twins (FluMist)</title>
          <description>Participants will be randomized to receive FluMist® (intranasal)</description>
        </group>
        <group group_id="B3">
          <title>Group B: Age 18-30 yo Identical Twins</title>
          <description>Participants to receive FluMist® (intranasal)</description>
        </group>
        <group group_id="B4">
          <title>Group C: Age 18-30 yo Fraternal Twins</title>
          <description>Participants to receive FluMist® (intranasal)</description>
        </group>
        <group group_id="B5">
          <title>Group D: Age 40-49 yo Identical Twins</title>
          <description>Participants to receive FluMist® (intranasal)</description>
        </group>
        <group group_id="B6">
          <title>Group E: Age 40-49 yo Fraternal Twins</title>
          <description>Participants to receive FluMist® (intranasal)</description>
        </group>
        <group group_id="B7">
          <title>Group F: 70-100 yo Identical Twins</title>
          <description>Participants to receive Fluzone® (intramuscular)</description>
        </group>
        <group group_id="B8">
          <title>Group G: 70-100 yo Nontwins</title>
          <description>Participants to receive Fluzone® (intramuscular)</description>
        </group>
        <group group_id="B9">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="8"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="6"/>
            <count group_id="B6" value="6"/>
            <count group_id="B7" value="10"/>
            <count group_id="B8" value="24"/>
            <count group_id="B9" value="72"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="10"/>
                    <measurement group_id="B8" value="24"/>
                    <measurement group_id="B9" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="4"/>
                    <measurement group_id="B8" value="18"/>
                    <measurement group_id="B9" value="42"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="6"/>
                    <measurement group_id="B9" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="10"/>
                    <measurement group_id="B8" value="24"/>
                    <measurement group_id="B9" value="68"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="10"/>
                    <measurement group_id="B8" value="23"/>
                    <measurement group_id="B9" value="65"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants From Each Arm Who Received Influenza Vaccine Vaccine</title>
        <time_frame>Day 0 to 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group A: Age 8-17 yo Identical Twins (IM)</title>
            <description>Participants will be randomized to receive Fluzone® (intramuscular)
Fluzone® (intramuscular): Licensed seasonal trivalent inactivated influenza vaccine (IIV3)</description>
          </group>
          <group group_id="O2">
            <title>Group A: Age 8-17 yo Identical Twins (IN)</title>
            <description>Participants will be randomized to receive FluMist® (intranasal
FluMist®: Licensed trivalent seasonal live attenuated influenza vaccine (LAIV3)</description>
          </group>
          <group group_id="O3">
            <title>Group B: 18-30 yo Identical Twins</title>
            <description>Participants to receive FluMist® (intranasal)
FluMist® (intranasal): Licensed trivalent seasonal live attenuated influenza vaccine (LAIV3)</description>
          </group>
          <group group_id="O4">
            <title>Group C: 18-30 yo Fraternal Twins</title>
            <description>Participants to receive Flumist® (intranasal)
Flumist® (intranasal): Licensed trivalent seasonal live attenuated influenza vaccine (LAIV3)</description>
          </group>
          <group group_id="O5">
            <title>Group D: 40-49 yo Identical Twins</title>
            <description>Participants to receive Flumist® (intranasal)
Flumist® (intranasal): Licensed trivalent seasonal live attenuated influenza vaccine (LAIV3)</description>
          </group>
          <group group_id="O6">
            <title>Group E: 40-49 yo Fraternal Twins</title>
            <description>Participants to receive Flumist® (intranasal)
Flumist® (intranasal): Licensed trivalent seasonal live attenuated influenza vaccine (LAIV3)</description>
          </group>
          <group group_id="O7">
            <title>Group F: 70-100 yo Twins</title>
            <description>Participants to receive Fluzone® (intramuscular)
Fluzone® (intramuscular): Licensed seasonal trivalent inactivated influenza vaccine (IIV3)</description>
          </group>
          <group group_id="O8">
            <title>Group G: 70-100 yo Non-twins</title>
            <description>Participants to receive Fluzone® (intramuscular)
Fluzone® (intramuscular): Licensed seasonal trivalent inactivated influenza vaccine (IIV3)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants From Each Arm Who Received Influenza Vaccine Vaccine</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="10"/>
                <count group_id="O8" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="10"/>
                    <measurement group_id="O8" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Related Adverse Events</title>
        <time_frame>Day 0 to 28 post-immunization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group A: Age 8-17 yo Identical Twins (IM)</title>
            <description>Participants will be randomized to receive Fluzone® (intramuscular)
Fluzone® (intramuscular): Licensed seasonal trivalent inactivated influenza vaccine (IIV3)</description>
          </group>
          <group group_id="O2">
            <title>Group A: Age 8-17 yo Identical Twins (IN)</title>
            <description>Participants will be randomized to receive FluMist® (intranasal)
FluMist® (intranasal): Licensed trivalent seasonal live attenuated influenza vaccine (LAIV3)</description>
          </group>
          <group group_id="O3">
            <title>Group B: 18-30 yo Identical Twins</title>
            <description>Participants to receive FluMist® (intranasal)
FluMist® (intranasal): Licensed trivalent seasonal live attenuated influenza vaccine (LAIV3)</description>
          </group>
          <group group_id="O4">
            <title>Group C: 18-30 yo Fraternal Twins</title>
            <description>Participants to receive FluMist® (intranasal)
FluMist® (intranasal): Licensed trivalent seasonal live attenuated influenza vaccine (LAIV3)</description>
          </group>
          <group group_id="O5">
            <title>Group D: 40-49 yo Identical Twins</title>
            <description>Participants to receive FluMist® (intranasal)
FluMist® (intranasal): Licensed trivalent seasonal live attenuated influenza vaccine (LAIV3)</description>
          </group>
          <group group_id="O6">
            <title>Group E: 40-49 yo Fraternal Twins</title>
            <description>Participants to receive FluMist® (intranasal)
FluMist® (intranasal): Licensed trivalent seasonal live attenuated influenza vaccine (LAIV3)</description>
          </group>
          <group group_id="O7">
            <title>Group F: 70-100 yo Twins</title>
            <description>Participants to receive Fluzone® (intramuscular)
Fluzone® (intramuscular): Licensed seasonal trivalent inactivated influenza vaccine (IIV3)</description>
          </group>
          <group group_id="O8">
            <title>Group G: 70-100 yo Non-twins</title>
            <description>Participants to receive Fluzone® (intramuscular)
Fluzone® (intramuscular): Licensed seasonal trivalent inactivated influenza vaccine (IIV3)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Related Adverse Events</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="10"/>
                <count group_id="O8" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Lymphocyte Response to Influenza Immunization</title>
        <description>Compare lymphocyte responses at Days 6-14 and the lymphocyte and serology responses at Day 28 post-immunization following annual administration of the influenza vaccines</description>
        <time_frame>Day 6-28 post-immunization</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Day 0 to Day 28 of study participation</time_frame>
      <desc>Clinical Assessment performed at each visit</desc>
      <group_list>
        <group group_id="E1">
          <title>Group A: Age 8-17 yo Identical Twins (Fluzone)</title>
          <description>Participants will be randomized to receive Fluzone® (intramuscular)</description>
        </group>
        <group group_id="E2">
          <title>Group A: Age 8-17 yo Identical Twins (Flumist)</title>
          <description>Participants will be randomized to receive Flumist® (intranasal)</description>
        </group>
        <group group_id="E3">
          <title>Group B: 18-30 yo Identical Twin Pairs</title>
          <description>Participants to receive Flumist® (intranasal)
Flumist® (intranasal): Licensed trivalent seasonal live attenuated influenza vaccine (LAIV3)</description>
        </group>
        <group group_id="E4">
          <title>Group C: 18-30 yo Fraternal Twins</title>
          <description>Participants to receive Flumist® (intranasal)
Flumist® (intranasal): Licensed trivalent seasonal live attenuated influenza vaccine (LAIV3)</description>
        </group>
        <group group_id="E5">
          <title>Group D: 40-49 yo Identical Twins</title>
          <description>Participants to receive Flumist® (intranasal)
Flumist® (intranasal): Licensed trivalent seasonal live attenuated influenza vaccine (LAIV3)</description>
        </group>
        <group group_id="E6">
          <title>Group E: 40-49 yo Fraternal Twins</title>
          <description>Participants to receive Flumist® (intranasal)
Flumist® (intranasal): Licensed trivalent seasonal live attenuated influenza vaccine (LAIV3)</description>
        </group>
        <group group_id="E7">
          <title>Group F: 70-100 yo Twins</title>
          <description>Participants to receive Fluzone® (intramuscular)
Fluzone® (intramuscular): Licensed seasonal trivalent inactivated influenza vaccine (IIV3)</description>
        </group>
        <group group_id="E8">
          <title>Group G: 70-100 yo Non-twins</title>
          <description>Participants to receive Fluzone® (intramuscular)
Fluzone® (intramuscular): Licensed seasonal trivalent inactivated influenza vaccine (IIV3)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Cornelia Dekker</name_or_title>
      <organization>Stanford University School of Medicine, Dept. of Pediatrics</organization>
      <phone>650-724-4437</phone>
      <email>cdekker@stanford.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

